相关实验视频

Updated: Jan 13, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

基于结构的虚拟查发现了具有抗癌活性强大的PLK1抑制剂

Qian Zhang¹, Wenxin Zhu¹, Yi Cai¹

¹School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China.

Journal of chemical information and modeling

|January 6, 2026

概括

研究人员使用计算实验方法确定了用于癌症治疗的强有力的PLK1抑制剂. 化合物BDE30671203具有很高的选择性,并诱导癌细胞循环停止和亡.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
计算生物学计算生物学

背景情况:

波罗样酶1 (PLK1) 是细胞循环进展的关键调节剂,也是癌症治疗的有希望的标.
开发选择性PLK1抑制剂对于有效的癌症治疗至关重要.

研究的目的:

通过结合计算和实验策略,识别和验证新的选择性PLK1抑制剂.
评估已识别的抑制剂在癌细胞中的抗增殖和机械效应.

主要方法:

利用了一个管道,包括酶支架优先级,基于结构的对接,分子动力学 (MD) 模拟.
进行了体外生化和细胞分析,包括抗增殖,细胞循环停止和亡研究.
对AURKA和AURKB等相关激酶进行了激酶选择性分析.

主要成果:

确定了BDE30671203和PB4767006058,它们与PLK1.1具有强烈的结合亲和力.
BDE30671203在七个癌细胞系中显示出强大的PLK1抑制 (IC50 = 2.163 ± 0.401 nM) 和显著的抗增殖作用 (IC50 < 10 μM).
BDE30671203诱导了G2/M停止和亡,降低了关键细胞循环调节器和Bcl-2的调节,并表现出高选择性 (>450倍AURKA,>1200倍AURKB).

结论:

这项研究为PLK1向癌症药物发现提供了有前途的化学起点.
一个强大的计算实验选策略用于酶抑制剂的发现得到了验证.
BDE30671203是一种具有治疗潜力的高度选择性的PLK1抑制剂.

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

Published on: May 12, 2017

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...